

WaveSense, Inc. Introduces nRich^{DX}™ for Molecular Diagnostics Market

System Introduction at the Association of Molecular Pathology (AMP) 2016 Annual Meeting

November 30, 2016

IRVINE, Calif., Nov. 30, 2016 -- WaveSense, Inc. (www.wavesense.com) the leader in targeted cell isolation and enrichment, announced today the introduction of the nRich^{DX} system for the bulk isolation of target cells and nucleic acids from liquid biopsies. The nRich^{DX} utilizes WaveSense's proprietary paramagnetic bead technology to enable the capture of circulating tumor cells (CTCs) and cell free DNA or RNA (cfDNA or cfRNA) in quantities sufficient for analysis by Next Generation Sequencing (NGS) and PCR techniques. The system can capture cells and nucleic acids from an array of sample types including blood, urine and bone marrow and is specifically designed and optimized for high volume, low yield specimens. The nRich^{DX} system is positioned to complement the company's already successful EpiSep® direct-to-slide enrichment technology that services the cytogenetic (FISH) market.

The use of liquid biopsies in molecular diagnostics has become an integral part of the diagnosis and treatment of disease. With this, the use of NGS and PCR is now standard practice in the downstream analysis of nucleic acids in both clinical and pharmaceutical laboratories. The WaveSense nRich^{DX} enrichment system is a powerful liquid biopsy tool that ensures the optimal isolation of the correct cell types in quantities sufficient for molecular analysis.

"The continued development of liquid biopsy will make significant and important changes in the diagnostic paradigms of cancer patients as well as in the approval of new chemotherapeutics," said WaveSense CEO William Curtis, "The nRich^{DX} system is well positioned to become the industry standard for the delivery of specific target cell populations and nucleic acids for downstream analysis via NGS, PCR and other molecular platforms."

About WaveSense

WaveSense, based in Irvine, CA (www.wavesense.com) is the leader in targeted cell isolation and enrichment from liquid biopsies. The WaveSense In Vitro diagnostic (IVD) product line provides the most sensitive targeted cell enrichment solution, requiring only a small specimen to deliver the maximum number of pure target cells while simultaneously eliminating background cells. Without the need for expensive capital equipment, WaveSense technology enables enhanced patient diagnostic and management outcomes by optimizing the results of downstream diagnostic modalities including IHC, FISH, PCR, SNP, Gene Expression and NGS. The WaveSense platform fulfills the need to improve workflow, test sensitivity and test results while increasing revenue and reducing operational costs and complexity. WaveSense manufactures the only FDA-listed IVD and CE-IVD products for paramagnetic coupled antibody targeted cell enrichment in the US and EU.

For more information, visit www.wavesense.com or email: info@wavesense.com

WAVESENSE
enriching Patient Lives